Free Trial

HCA Healthcare (HCA) Stock Forecast & Price Target

$322.16
+0.43 (+0.13%)
(As of 07/19/2024 ET)

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 18 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for HCA.

Consensus Price Target

$327.06
1.52% Upside
High Forecast$396.00
Average Forecast$327.06
Low Forecast$271.00

According to the 18 analysts' twelve-month price targets for HCA Healthcare, the average price target is $327.06. The highest price target for HCA is $396.00, while the lowest price target for HCA is $271.00. The average price target represents a forecasted upside of 1.52% from the current price of $322.16.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
14 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$327.06$325.59$314.05$306.78
Forecasted Upside1.52% Upside11.09% Upside11.32% Upside15.28% Upside
Get HCA Healthcare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HCA and its competitors with MarketBeat's FREE daily newsletter.

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HCA Healthcare Stock vs. The Competition

TypeHCA HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside1.52% Upside3,241.48% Upside10.06% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Barclays
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$367.00 ➝ $376.00+19.23%
7/9/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$335.00 ➝ $335.00+5.63%
6/28/2024Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Boost TargetBuy ➝ Buy$359.00 ➝ $375.00+14.85%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$327.00 ➝ $332.00-0.86%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$396.00+21.88%
4/30/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$371.00 ➝ $360.00+16.04%
4/29/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$322.00 ➝ $329.00+6.37%
4/29/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$330.00 ➝ $345.00+12.49%
3/28/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$303.00 ➝ $315.00-5.17%
1/31/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$320.00 ➝ $345.00+12.32%
1/31/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$300.00 ➝ $330.00+9.45%
1/4/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$277.00 ➝ $301.00+9.85%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$271.00+5.23%
11/10/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$280.00+20.26%
10/25/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$325.00 ➝ $275.00+21.19%
10/25/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$324.00 ➝ $279.00+22.87%
7/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$311.00 ➝ $316.00+14.31%
6/28/20231-800-FLOWERS.COM
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/28/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/10/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $310.00+13.12%
4/24/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$325.00 ➝ $350.00+23.24%
4/24/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $320.00+13.79%
4/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$294.00 ➝ $323.00+14.86%
1/30/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$238.00 ➝ $292.00+14.61%
1/13/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$237.00 ➝ $296.00+16.01%
12/16/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$238.00 ➝ $286.00+19.64%
7/25/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$238.00+19.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:36 PM ET.

HCA Forecast - Frequently Asked Questions

What is HCA Healthcare's forecast for 2024?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $327.06, with a high forecast of $396.00 and a low forecast of $271.00.

Should I buy or sell HCA Healthcare stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There are currently 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCA shares.

Does HCA Healthcare's stock price have much upside?

According to analysts, HCA Healthcare's stock has a predicted upside of 11.63% based on their 12-month stock forecasts.

Has HCA Healthcare been upgraded by Wall Street analysts recently?

Over the previous 90 days, HCA Healthcare's stock had 1 upgrade by analysts.

What analysts cover HCA Healthcare?

HCA Healthcare has been rated by research analysts at Baird R W, Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Oppenheimer, Robert W. Baird, Royal Bank of Canada, and TD Cowen in the past 90 days.

Do Wall Street analysts like HCA Healthcare more than its competitors?

Analysts like HCA Healthcare more than other "medical" companies. The consensus rating score for HCA Healthcare is 2.83 while the average consensus rating score for "medical" companies is 2.72. Learn more on how HCA compares to other companies.


This page (NYSE:HCA) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners